Lenz

LENZ Therapeutics commercializes VIZZ® 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia.

Domain
Healthcare
Status
IPO’d/​Acquired
Acquisition Announcement Date
2024
IPO Date
2021
Stage of Initial Investment
Series A
Initial Investment Year
2020